Results 1 to 10 of about 46,843 (269)

Itraconazole Increases Ibrutinib Exposure 10‐Fold and Reduces Interindividual Variation—A Potentially Beneficial Drug‐Drug Interaction

Clinical and Translational Science, 2020
The oral bioavailability of ibrutinib is low and variable, mainly due to extensive first‐pass metabolism by cytochrome P450 (CYP) 3A4. The unpredictable exposure can compromise its safe and effective dosing.
Tuija Tapaninen, Aleksi M. Olkkola, Aleksi Tornio, Mikko Neuvonen, Erkki Elonen, Pertti J. Neuvonen, Mikko Niemi, Janne T. Backman   +7 more
doaj   +2 more sources

Exploring the therapeutic mechanism of itraconazole combined with ritonavir on Candida albicans infection through network pharmacology and molecular docking [PDF]

Frontiers in Pharmacology
BackgroundAutophagy induced by itraconazole and ritonavir was found involved in the pathogenesis of C. albicans. This study was designed to explore the possible molecular mechanism of itraconazole and ritonavir in the treatment of Candida albicans ...
Yiyang Feng, Wenli Feng, Jing Yang, Yan Ma   +3 more
doaj   +2 more sources

Itraconazole induces apoptosis and cell cycle arrest via inhibiting Hedgehog signaling in gastric cancer cells

Journal of Experimental & Clinical Cancer Research, 2017
Background Itraconazole has been proved therapeutically effective against a variety of human cancers. This study assessed the effect of itraconazole on the Hedgehog (Hh) pathway and proliferation of human gastric cancer cells.
Qiang Hu, Yi-Chao Hou, Jiao Huang, Jing-Yuan Fang, Hua Xiong   +4 more
doaj   +2 more sources

Observational study of the recent efficacy and economy of itraconazole vs. voriconazole in perioperative pulmonary aspergillosis [PDF]

Frontiers in Surgery
BackgroundAntifungal therapy is a common treatment option for pulmonary aspergillosis, but its use to prevent recurrence and relieve symptoms in patients with pulmonary aspergillosis remains controversial.
Peng Chen, Xiao Zhang, Xinzhe Zheng, Yang Tang, Yongxiang Song, Gang Xu, Xixian Ke, Cheng Chen   +7 more
doaj   +2 more sources

The anti-cancer effects of itraconazole in epithelial ovarian cancer

Scientific Reports, 2017
We assessed the anti-proliferative activity of itraconazole using an EOC cell line (SKOV3ip1) and endothelial cell lines (HUVEC & SVEC4-10). We also examined angiogenesis (VEGFR2, p-ERK, p-PLCr1/2), hedgehog (Gli1, Ptch1, SMO), and mTOR (pS6K1) signaling
Chel Hun Choi, Ji-Yoon Ryu, Young-Jae Cho, Hye-Kyung Jeon, Jung-Joo Choi, Kris Ylaya, Yoo-Young Lee, Tae-Joong Kim, Joon-Yong Chung, Stephen M. Hewitt, Byoung-Gie Kim, Duk-Soo Bae, Jeong-Won Lee   +12 more
doaj   +2 more sources

Gender differences in concentration of itraconazole and hydroxyitraconazole [PDF]

Halo 194, 2021
Introduction: Itraconazole is an antifungal drug belonging to the triazole group. After oral application, it is rapidly absorbed, but its bioavailability is reduced due to an intensive first-pass through the liver metabolism effect.
Stanojković Tijana, Miljković Milijana, Rančić Nemanja, Kovačević Aleksandra, Dragojević-Simić Viktorija   +4 more
doaj   +1 more source

475. Does Metabolite Matter? Defining Target Itraconazole and Hydroxy-itraconazole Serum Levels for Blastomycosis

Open Forum Infectious Diseases, 2022
Background Itraconazole is first-line treatment for mild-moderate blastomycosis and consolidation of moderate-severe disease. Itraconazole is metabolized to 3 metabolites, including an active metabolite hydroxy-itraconazole.
Danielle Hess, O. A. Abu Saleh, M. Enzler, P. Jannetto, Kristin Mara, Ryan W. Stevens, P. Vergidis, C. Rivera   +7 more
semanticscholar   +1 more source

Itraconazole Inhibits the Growth of Cutaneous Squamous Cell Carcinoma by Targeting HMGCS1/ACSL4 Axis

Frontiers in Pharmacology, 2022
Background: Cutaneous squamous cell carcinoma (cSCC) is a common cutaneous cancer with increasing incidence. Itraconazole has been identified as a potential anticancer drug candidate. However, the role of itraconazole in cSCC was still unclear.
Congcong Xu, Yating Zhuo, Yunyao Liu, Hao Chen   +3 more
doaj   +1 more source

The A756T Mutation of the ERG11 Gene Associated With Resistance to Itraconazole in Candida Krusei Isolated From Mycotic Mastitis of Cows

Frontiers in Veterinary Science, 2021
Candida krusei (C. krusei) has been recently recognized as an important pathogen involved in mycotic mastitis of cows. The phenotypic and molecular characteristics of 15 C.
Jun Du, Jun Du, Wenshuang Ma, Wenshuang Ma, Jiaqi Fan, Jiaqi Fan, Xiaoming Liu, Xiaoming Liu, Yujiong Wang, Yujiong Wang, Xuezhang Zhou, Xuezhang Zhou   +11 more
doaj   +1 more source

Overexpression of Both ERG11 and ABC2 Genes Might Be Responsible for Itraconazole Resistance in Clinical Isolates of Candida krusei. [PDF]

PLoS ONE, 2015
To study the main molecular mechanisms responsible for itraconazole resistance in clinical isolates of Candida krusei.The 14α-demethylases encoded by ERG11 gene in the 16 C.krusei clinical isolates were amplified by polymerase chain reaction (PCR), and ...
Xiaoyuan He, Mingfeng Zhao, Jinyan Chen, Rimao Wu, Jianlei Zhang, Rui Cui, Yanyu Jiang, Jie Chen, Xiaoli Cao, Yi Xing, Yuchen Zhang, Juanxia Meng, Qi Deng, Tao Sui   +13 more
doaj   +1 more source